Tools chosen: kalshi_direct claude_news claude_news gdelt_news wikipedia kalshi_related polymarket_related code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a long-horizon epidemiological question: a zero-WPV1 year requires interrupting transmission in Pakistan and Afghanistan (the only remaining endemic reservoirs) with a full calendar year of zero reported cases plus reporting lag. Key research is current-year WPV1 case counts from GPEI, the 2024 resurgence trend, vaccination-access conditions in Afghanistan/Pakistan, and the Kalshi price as the crowd anchor.

# Current state As of the most recent WHO/GPEI data (through 2026 YTD), wild poliovirus type 1 (WPV1) remains endemic in Afghanistan and Pakistan with no calendar year on record ever reaching zero cases. The lowest annual count in the last decade was 12 (2023); 2025 saw ~40 cases (WHO) or ~30-38 depending on source, down from a 2024 spike to 99. As of 2026, cases continue at a reduced pace (~6 cases reported globally through parts of 2026), but the resolution requires a full CALENDAR YEAR of zero WPV1 cases before 2030 — not merely a declining trend or low-case year. # Timeline of key events - 2019-2023: Pakistan WPV1 cases: 147→84→1(?)/6→20→6/12 (sources vary slightly); Afghanistan similar low-single/double digits; 2023 global total ~12 cases (confirmed, Nature/CIDRAP). - 2024: Global WPV1 cases spike to 99 (final EC count), a 4x+ increase in Afghanistan and 12x in Pakistan vs 2023 (confirmed, WHO EC statement). - 2024-09: Taliban suspends house-to-house vaccination campaigns in Afghanistan, shifting to site-to-site strategy (confirmed, RFE/RL). - 2025: Global WPV1 cases decline to ~40 (WHO, 9 Afghanistan/31 Pakistan) or ~30 in Pakistan alone per Wikipedia/AP — a roughly 50-60% YoY decline (confirmed, WHO Jan 2026 statement). - 2025 (mid-year): WHO Emergency Committee notes site-to-site campaigns in Afghanistan leave gaps; ~85% of Afghan polio cases occur in areas off-limits to house-to-house vaccinators (confirmed, Science/WHO EC). - 2025-10: WHO warns of $1.7bn funding shortfall through 2029 threatening eradication activities (confirmed, Al Jazeera). - 2026 (Jan-Aug): Global case count ~6 reported so far in 2026 (all Pakistan/Afghanistan), continued environmental positivity (13.1% in Pakistan per July 2026 report), sporadic new cases (Uruzgan Aug 2026), continued attacks on vaccination teams in Balochistan/KP (confirmed, GDELT/AP/ianslive). - 2026-03: WHO Emergency Committee reframes target: interrupt WPV1 transmission in 2026, stop cVDPV2 by 2028, certification later (confirmed, WHO 44th EC statement) — this is the latest official target, having slipped from original 2023→2026/2027→2026 framing. # Event Will there be at least one calendar year between 2024-2029 with zero reported wild poliovirus (WPV1) cases globally? # Outcomes to forecast - Yes (a zero-WPV1-case year occurs before 2030) - No (no such year occurs) # Kalshi market anchor **Current YES price: 4.60%** (down from 30-day high of 12.70%; -1.80% over 7 days, -2.80% over 30 days). Average daily volume ~93 contracts over 38 days of data — thin but consistent trading, trending downward, reflecting worsening sentiment on near-term eradication. # Sub-question answers 1. **WPV1 cases by year/country** — 2023: 12 total (6 Afghanistan, 6 Pakistan). 2024: 99 total (spike). 2025: ~40 total (9 Afghanistan, 31 Pakistan per WHO), Pakistan-only sources cite ~30. 2026 YTD: ~6 cases globally as of mid-2026 (claude_news/GDELT), all in Pakistan/Afghanistan. 2. **GPEI target date** — Repeatedly slipped: original 2023 target for last cases missed; extended to 2026, then WPV1-specific to 2027; most recent (March 2026 WHO EC) reframes as "interrupt transmission in 2026," cVDPV2 by 2028, with certification following later (WHO EC statements). 3. **Environmental surveillance** — Still widely positive but declining: 741 positive samples in 2024 → 80 in early 2025; Pakistan's environmental positivity rate was 13.1% as of July 2026 (down but still substantial), indicating ongoing silent circulation (WHO/GDELT). 4. **Vaccination access** — Afghanistan: Taliban suspended house-to-house campaigns Sept 2024, shifted to site-to-site, leaving ~85% of cases in areas off-limits to vaccinators (Science/WHO EC). Pakistan: security restrictions persist in Balochistan/KP with ongoing attacks on polio workers/police (200+ killed since 1990s; new 2026 incidents in Bajaur, Hangu) (AP/ianslive). 5. **Historical base rate** — No year has ever recorded zero WPV1 cases; closest approach was 2021 (Pakistan: 1 case; global ~5-6 cases per some counts). No precedent exists for a true zero year among endemic-country data (Wikipedia/isid.org). 6. **Kalshi price/related markets** — KXPOLIOELIM-30 at 4.60% YES, declining trend, thin volume (~93/day). No matching Polymarket markets found (0 matches for "polio"/"eradicated"). No other related Kalshi series beyond this one ticker. # Key facts (high-confidence, factual) 1. [Nature/CIDRAP] 2023: 12 global WPV1 cases, lowest recent year. 2. [WHO EC] 2024: 99 cases, a major resurgence. 3. [WHO, Jan 2026] 2025: ~40 cases, roughly 50-60% decline from 2024. 4. [WHO EC March 2026] Current official target: interrupt transmission in 2026, but this follows multiple prior missed deadlines (2023, 2026, 2027). 5. [Science/WHO EC] Afghanistan's shift to site-to-site vaccination leaves ~85% of cases in inaccessible areas. 6. [Al Jazeera] $1.7bn funding shortfall through 2029 threatens program activities. 7. [Wikipedia/isid.org] No calendar year has ever recorded zero WPV1 cases; 2021 came closest with very low counts but not zero. # Cross-market signals - Kalshi related: Only KXPOLIOELIM-30 itself found; no arbitrage market. - Polymarket: No matching markets ("polio," "eradicated" both zero hits). - Sportsbook implied: N/A (not applicable to health/epidemiology event). # Analyst opinions and speculation - Code-execution Fermi model: blended estimate ~25-35% probability of a zero-case year by 2030, heavily dependent on whether case trajectory continues declining (fast-interruption scenario: 80-91%) vs. stalls/rebounds (0-9%). Overdispersion (conflict-driven volatility) modestly raises zero-probability even at moderate case counts. - Health Policy Watch/Atlantic Council: frame Pakistan-Afghanistan as a "single epidemiological bloc" via genetic linkage, implying interruption requires simultaneous success in both — a higher bar. - WHO EC frames early-mid 2026 as a "critical window" but funding gaps and Taliban restrictions are explicitly cited as major risks to hitting even the newest target. # Directional lean per outcome - **Yes**: 2025 showed steep decline (99→~40, ~-60%); if this trend continues at pace, low single digits are plausible within 1-2 years, and even a brief interruption could produce one zero year before 2030. Historical WPV1 elimination in other regions (Nigeria 2016) shows declines can culminate in zero. - **No**: No year has ever hit zero; 2024 proved sharp rebounds are possible even after low years (2023's 12 → 2024's 99); Taliban restrictions, security attacks, and funding shortfalls are structural, persistent barriers; environmental surveillance still shows circulation in inaccessible reservoirs (KP, Balochistan, southern Afghanistan). Kalshi's declining price (12.7%→4.6%) reflects market repricing toward "No." # Gaps / unknowns - No 2026 full-year case total available yet (only partial-year data through mid-2026). - Unclear whether "zero cases" requires zero cases in ALL countries globally (including any non-endemic imports) or just endemic countries — description says "any reported wild cases of poliovirus 1" globally, which is a high bar. - No visibility into 2027-2029 funding commitments or political developments (Taliban policy, Pakistan security) that could shift trajectory. # Calibration anchors - Kalshi current YES price: 4.60% (declining trend, thin volume) — the primary anchor. - No historical precedent for a zero-WPV1-case year in Pakistan/Afghanistan era; closest was ~1-6 cases (2021, 2023). - Fermi/code model blended estimate: ~25-35%, but this is more optimistic than the market's 4.6%, largely due to weighting a "fast interruption" tail scenario the market appears to discount heavily given 2024's rebound and persistent structural barriers.

1. Both forecasts land at 7-8% YES, essentially ignoring the Fermi/code model's 25-35% blended estimate cited in the brief—neither explains why they discount that model so heavily beyond vague "structural barriers" language, leaving a large unexplained gap between their number and an alternative quantitative estimate in the evidence. 2. Neither forecaster grapples with the "single epidemiological bloc" framing (Health Policy Watch/Atlantic Council) that argues Pakistan and Afghanistan must simultaneously interrupt transmission—this is a substantive reason to weight No even higher than the market price, yet both nudge upward from Kalshi rather than treating this as a reason to stay at or below 4.6%. 3. Both treat 2026 as "already off the table" using only partial-year data (~6 cases through mid-2026), but neither addresses the definitional ambiguity flagged in the Gaps section—whether "zero cases" means zero globally including any imported/non-endemic cases, which is a stricter bar that should push probability down, not get glossed over. 4. Neither forecast explicitly addresses the funding shortfall's forward-looking effect on 2027-2029 (the only years still live for a zero-year), despite the brief noting no visibility into 2027-2029 funding commitments—this is treated as a generic risk factor rather than a specific reason the later years (where the "tail scenario" must occur) are structurally worse-resourced. 5. Both forecasters use nearly identical rationale and land within 1 point of each other (7% vs 8%), suggesting anchoring convergence on Kalshi's price rather than independent analysis; neither considers whether Kalshi's thin volume (~93 contracts/day) and small market size warrant a wider confidence interval or larger deviation from the anchor. 6. Neither discusses the asymmetry that a single verified zero-year among six candidate years (2024-2029, with 2024 already failed and 2026 likely failed) requires increasingly favorable conditions given only 3-4 years remain, and that GPEI's serial target-slippage (2023→2026→2027→"2026 again") is itself evidence against any specific future year hitting zero, which should anchor closer to Kalshi's 4.6% rather than above it.

6% (64% confidence)

Yes: 6% No: 94%

Only 2027–2029 remain live candidate years (2024 failed at 99 cases, 2025 at ~40, 2026 already has ~6 reported), and a 2029 zero would be difficult to verify by the close date given reporting lags — so realistically 2027–2028 must deliver a fully clean calendar year globally, including any imported WPV1 cases. That is a bar never met in the history of the program, and the structural obstacles are persistent rather than transient: Taliban site-to-site-only campaigns leaving ~85% of Afghan cases in inaccessible areas, continued attacks on vaccinators in Balochistan/KP, 13.1% environmental positivity indicating silent circulation, and a $1.7bn funding gap that specifically degrades capacity in the very years the tail scenario would need to occur. The Fermi model's 25–35% overweights a 'fast interruption' branch that the 2023→2024 rebound (12→99) and serial target slippage (2023→2026→2027→2026) directly falsify as a reliable pattern; the Pakistan–Afghanistan 'single epidemiological bloc' linkage further requires simultaneous success in both, raising the bar. I therefore stay close to the declining Kalshi anchor (12.7%→4.6%) rather than nudging above it as both forecasters did, allowing only a small premium for thin-market noise and the genuine possibility that the 2025–26 decline culminates in interruption during 2027.

Total pipeline time: 258.2s